Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720018 · ClinicalTrials.gov registry record · Phase 1
Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers
A Phase 1 study, sponsored by NuPathe.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00720018 is a Phase 1 study that has completed, run by NuPathe. The registered enrollment target is 4 participants.
The verdict
NCT00720018, a Phase 1 study, has completed, sponsored by NuPathe.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The primary objective is to compare the pharmacokinetics (PK) profiles among five NP101 patches in healthy volunteers. The secondary objective is to evaluate the safety of NP101 in healthy volunteers.
Interventions
- DRUG NP101 Sumatriptan Iontophoretic Transdermal Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2008-06 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00720018
The ClinicalTrials.gov registry entry for NCT00720018 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NuPathe, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NP101 Sumatriptan Iontophoretic Transdermal Patch is the first listed.
NCT00720018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00720018 about?
NCT00720018 is a clinical study titled "Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers". The primary objective is to compare the pharmacokinetics (PK) profiles among five NP101 patches in healthy volunteers. The secondary objective is to evaluate the safety of NP101 in healthy volunteers.
What is the current status of trial NCT00720018?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2008-06. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00720018?
The interventions under investigation include: NP101 Sumatriptan Iontophoretic Transdermal Patch (DRUG).
Who is sponsoring clinical trial NCT00720018?
This trial is sponsored by NuPathe, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.